WO2009023053A3 - Use of rsk inhibitors to impede intracellular pathogen infections - Google Patents

Use of rsk inhibitors to impede intracellular pathogen infections Download PDF

Info

Publication number
WO2009023053A3
WO2009023053A3 PCT/US2008/006153 US2008006153W WO2009023053A3 WO 2009023053 A3 WO2009023053 A3 WO 2009023053A3 US 2008006153 W US2008006153 W US 2008006153W WO 2009023053 A3 WO2009023053 A3 WO 2009023053A3
Authority
WO
WIPO (PCT)
Prior art keywords
impede
rsk
inhibiting
intracellular pathogen
pathogen infections
Prior art date
Application number
PCT/US2008/006153
Other languages
French (fr)
Other versions
WO2009023053A2 (en
Inventor
Deobrah A Lannigan-Macara
Jeffrey A Smith
Original Assignee
Univ Virginia
Luna Innovations Inc
Deobrah A Lannigan-Macara
Jeffrey A Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia, Luna Innovations Inc, Deobrah A Lannigan-Macara, Jeffrey A Smith filed Critical Univ Virginia
Publication of WO2009023053A2 publication Critical patent/WO2009023053A2/en
Publication of WO2009023053A3 publication Critical patent/WO2009023053A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01037—Protein kinase (2.7.1.37)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A composition comprising a RSK activity inhibiting agent is provided for inhibiting the establishment or maintenance of an intracellular pathogenic infection by pathogens whose pathogenicity derives in part from the pathogens ability to impede endosomal/phagosomal maturation in the host cell. The RSK specific inhibitors used in accordance with the disclosed composition and methods can be selected from any inhibiting moiety including by not limited to anti-sense oligonucleotides, interfering oligonucleotide and kaempferol 3-O-(3',4'-di-O-acetyl- α-L-rhamnopyranoside) and related compounds.
PCT/US2008/006153 2007-05-18 2008-05-14 Use of rsk inhibitors to impede intracellular pathogen infections WO2009023053A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93087607P 2007-05-18 2007-05-18
US60/930,876 2007-05-18

Publications (2)

Publication Number Publication Date
WO2009023053A2 WO2009023053A2 (en) 2009-02-19
WO2009023053A3 true WO2009023053A3 (en) 2009-05-14

Family

ID=40351335

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/006153 WO2009023053A2 (en) 2007-05-18 2008-05-14 Use of rsk inhibitors to impede intracellular pathogen infections

Country Status (1)

Country Link
WO (1) WO2009023053A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011019995A2 (en) * 2009-08-14 2011-02-17 Hecht Sidney M Synthesis and identification of novel rsk-specific inhibitors
CN109847063B (en) * 2018-12-26 2023-02-28 南方医科大学皮肤病医院（广东省皮肤病医院、广东省皮肤性病防治中心、中国麻风防治研究中心） Application of RSK signal pathway inhibitor in inhibiting chlamydia trachomatis infection
CN112641774A (en) * 2020-12-22 2021-04-13 浙江大学 Application of chalcone and flavonoid compound in preparation of antibacterial drugs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040023992A1 (en) * 2002-05-20 2004-02-05 Jagabandhu Das Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
US20070049539A1 (en) * 2002-06-12 2007-03-01 Smith Jeffrey A Rsk inhibitors and therapeutic uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040023992A1 (en) * 2002-05-20 2004-02-05 Jagabandhu Das Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
US20070049539A1 (en) * 2002-06-12 2007-03-01 Smith Jeffrey A Rsk inhibitors and therapeutic uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOUL ET AL.: "Interplay Between Mycobacteria and Host Signalling Pathways.", NATURE REVIEWS MICROBIOLOGY, vol. 2, 2004, pages 189 - 202 *

Also Published As

Publication number Publication date
WO2009023053A2 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
WO2008079460A3 (en) Tyrosine kinase inhibitors for prevention or treatment of infection
WO2010090860A3 (en) Methods and compositions for treating bacterial infection
WO2009026166A3 (en) Antiinfective flavonol compounds and methods of use thereof
GB2480773B (en) Compositions for the treatment of diarrhea caused by virulent E. coli infections
WO2007131072A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
WO2009062112A3 (en) Use of tam receptor inhibitors as antimicrobials
WO2010063996A3 (en) Antibacterial compounds
WO2005072826A3 (en) Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
EA033311B1 (en) Benzoxaborole derivatives as antibacterial agents
WO2010084115A3 (en) Antiviral agents
WO2006128089A3 (en) Compositions and methods for treating tissue
GB2480772A (en) Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus
WO2009095226A3 (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
WO2012047762A3 (en) Antifungal agents
EP2279662A3 (en) 5,7,4'-trihydroxy-3',5'-dimethoxyflavone as an antibacterial agent
WO2009088549A3 (en) Methods of inhibiting bacterial virulence and compounds relating thereto
WO2007118198A3 (en) 2-METHYLENE-1α,25-DIHYDROXY-19,21-DINORVITAMIN D3 ANALOGS AND USES THEREOF
WO2009118253A3 (en) Hair styling composition
TW200630378A (en) Macrolones-amino substituted quinolones
UA95715C2 (en) Phosphadiazine derivatives, pharmaceutical composition and use thereof
WO2011019995A3 (en) Synthesis and identification of novel rsk-specific inhibitors
FR2929509B1 (en) USE OF ALKYL GLYCOSIDES OR ALKYL GLYCOSIDE MIXTURES AS AGENTS FOR INHIBITING MICROBIAL GROWTH AND COMPOSITIONS CONTAINING SAID ALKYL GLYCOSIDES
WO2006108681A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against bacteria
WO2008071961A8 (en) 2-quinolinone and 2-quinoxalinone- derivatives and their use as antibacterial agents
WO2009023053A3 (en) Use of rsk inhibitors to impede intracellular pathogen infections

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08827541

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08827541

Country of ref document: EP

Kind code of ref document: A2